Aphasia is a loss of language ability, and frontotemporal dementia (FTD) is a group of brain diseases caused by degeneration of the frontal and temporal lobes. The two are connected through a specific condition called primary progressive aphasia, or PPA, which is a type of frontotemporal dementia where language slowly breaks down as brain tissue deteriorates. Unlike a stroke, which causes sudden aphasia, PPA erodes language gradually over months and years.
FTD is the second most common cause of dementia in people under 65. Its prevalence peaks between ages 65 and 69, though symptoms can appear as early as the 40s. While Alzheimer’s disease accounts for about 70% of late-onset dementia cases, FTD is a major player in younger-onset dementia, making it particularly devastating for people still in their working years.
How PPA Fits Within Frontotemporal Dementia
Frontotemporal dementia isn’t a single disease. It’s an umbrella term covering several conditions that share a common feature: progressive damage to the front and side regions of the brain. The most common form is behavioral variant FTD (bvFTD), where personality and behavior change first. Primary progressive aphasia is the other major branch, where language is the first casualty.
Not everyone with PPA meets the criteria for dementia right away. Early on, language may be the only thing affected, and the person can still manage daily tasks, make decisions, and live independently. The term “dementia” typically applies once cognitive decline becomes severe enough to interfere with a person’s ability to function on their own. Over time, though, most people with PPA do progress to that point. As the disease advances, the symptom profiles of PPA and behavioral variant FTD start to blur: people who began with language problems often develop personality changes similar to bvFTD, and people initially diagnosed with bvFTD may develop aphasia later.
The Three Variants of PPA
PPA comes in three distinct forms, each affecting language in a different way and involving different parts of the brain.
Nonfluent-Agrammatic Variant
Speech becomes effortful and halting. Grammar breaks down, so sentences come out short and telegraphic, missing small connecting words. Many people also develop difficulty planning the mouth movements needed for speech, a problem called apraxia of speech. Brain imaging shows damage concentrated in the left frontal region, including areas responsible for motor planning of speech. This variant tends to progress more quickly than the semantic form, with an average survival of about 7 years from symptom onset.
Semantic Variant
The core problem here is loss of word meaning. A person might look at a picture of a camel and have no idea what to call it, or hear the word “camel” and not know what it refers to. Speech itself remains fluent and grammatically correct, but it becomes increasingly empty as vocabulary erodes. Brain imaging reveals shrinkage in the front portions of both temporal lobes, with the left side more affected than the right. This is the slowest-progressing variant, with average survival around 12 years from symptom onset and 7.3 years from diagnosis.
Logopenic Variant
People with this form have trouble finding the right word mid-sentence, leading to long pauses in conversation. They also struggle to repeat longer sentences. Unlike the nonfluent variant, their grammar stays intact and speech isn’t effortful. The damage centers on the left side of the brain where the temporal and parietal lobes meet. Average survival from symptom onset is about 7.6 years.
What Happens in the Brain
At the cellular level, FTD involves the buildup of misfolded proteins inside brain cells. The two main culprits are a protein called tau and another called TDP-43. In healthy brains, both proteins serve important functions. In FTD, they fold into abnormal shapes, clump together, and either become toxic to neurons or lose their ability to do their normal jobs. Research in animal models suggests that both mechanisms contribute: the clumps themselves damage cells, and the loss of the protein’s normal function in the cell nucleus causes additional harm.
Different protein patterns tend to map onto different clinical presentations. Abnormal TDP-43 deposits in the outer layers of the brain’s cortex are commonly found in both behavioral variant FTD and the nonfluent form of PPA. The logopenic variant, by contrast, is more often linked to Alzheimer’s-type pathology, which is one reason it sometimes sits at the boundary between FTD and Alzheimer’s disease.
Genetics and Risk
FTD has a stronger genetic component than most other dementias. Roughly 10 to 20% of all FTD cases are clearly familial, meaning they run in families with an identifiable gene mutation. Mutations in the progranulin gene account for about 20 to 25% of familial cases and roughly 10% of all FTD cases. Other important genetic mutations involve the tau gene and a gene called C9orf72, which is also linked to ALS (Lou Gehrig’s disease). Having a first-degree relative with FTD does increase risk, though many cases occur in people with no known family history.
How PPA Is Diagnosed
Diagnosis typically starts when someone notices progressive trouble with language that can’t be explained by a stroke, tumor, or other cause. A neurologist will assess specific language abilities: naming objects, understanding single words, repeating sentences, forming grammatically correct sentences, and reading aloud. The pattern of deficits points toward a specific variant.
Brain imaging plays a central role. MRI scans can reveal characteristic patterns of brain shrinkage. In the semantic variant, imaging shows bilateral temporal lobe atrophy, including structures involved in memory and object recognition, with the left side more affected. In the nonfluent variant, the damage is more widespread across frontal regions, including the premotor areas and the bridge connecting the two brain hemispheres. These imaging patterns, combined with the clinical picture, allow neurologists to classify which variant a person has with reasonable confidence.
Treatment and Communication Support
There are currently no FDA-approved drugs that slow or stop PPA or FTD. The National Institute on Aging is actively funding research into new treatments, and clinical trials are underway, but as of 2025, no disease-modifying therapy exists. Medications are sometimes used to manage specific symptoms like depression, anxiety, or behavioral changes, but they don’t address the underlying brain degeneration.
The most effective intervention available is speech and language therapy. A speech-language pathologist can assess exactly which language abilities are affected and build a treatment plan around preserving what remains. Specific approaches include errorless learning (practicing words in a way that minimizes mistakes), semantic feature training (strengthening word knowledge by associating words with their properties), and script training (rehearsing common conversational exchanges). Several of these therapies have shown sustained improvements lasting up to six months in studies.
For word-finding and naming difficulties, structured practice with pictures and word associations has shown measurable results. For fluency problems, video-based script training and structured oral reading have helped improve grammatical accuracy and reduce speech errors. Some research centers are also exploring brain stimulation techniques combined with language therapy, which have shown promise in boosting naming accuracy beyond what therapy alone achieves.
As the disease progresses, the focus of therapy shifts from restoring language to building alternative communication strategies. This might include using tablets or smartphones with communication apps, creating personalized picture boards, or training family members in supported conversation techniques. Planning for these transitions early, while the person can still participate in choosing their tools, makes the later stages more manageable.
How the Disease Progresses
PPA typically begins subtly. A person might struggle to find a word here and there, or their spelling might start to slip. At this stage, friends and family often attribute it to normal aging or stress. Over the next few years, language difficulties become unmistakable. Conversations grow harder, reading and writing may decline, and the person begins withdrawing from social situations.
In the middle stages, language loss becomes severe enough to affect independence. Following group conversations, using the phone, and managing finances through written communication all become difficult. Behavioral changes often emerge during this period, even in people who started with purely language symptoms. These can include apathy, loss of motivation, and reduced self-awareness. Research shows that PPA patients maintain good insight into their condition early on, but awareness of their own symptoms, particularly apathy, diminishes over time.
In later stages, most people with PPA develop broader cognitive decline and may need full-time care. Some also develop motor symptoms resembling Parkinson’s disease or other movement disorders, which tend to accelerate decline. The semantic variant progresses most slowly, with an average of 12 years from first symptoms. The nonfluent and logopenic variants move faster, averaging about 7 years from onset. These are averages, and individual trajectories vary considerably.